Amicus Therapeutics Inc (FRA:AM6)
€ 9.3 0.2 (2.2%) Market Cap: 2.82 Bil Enterprise Value: 3.01 Bil PE Ratio: 0 PB Ratio: 16.43 GF Score: 78/100

Amicus Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 10:15PM GMT
Release Date Price: €12.2
Anupam Rama JP Morgan;Analyst

Welcome everybody to the 42nd Annual JP Morgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. And I'm joined by my squad Malcolm Kuno, Priyanka Grover, and LaRhea Hall.

Our next presenting company is Amicus, and presenting on behalf of the company, we've CEO, Brad Campbell. Brad?

Bradley Campbell Amicus Therapeutics
Inc. - President and CEO

Thanks a lot, Anupam, JPMorgan, for hosting us. It's great to be here. It's always a great way to start the year. Everybody's been reflecting on how nice it is to have sunshine outside, a better macro environment. It's a good time to be a biotech CEO with two commercial products, and we'll talk a lot more about Amicus. Of course, I'll be making forward looking statements. As always, we refer you to our Safe Harbor provisions.

Amicus Therapeutics, we are a company that was founded on the idea that we could make next-generation therapies for people living with rare and orphan diseases. And after almost 20 years

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot